SecBot SecBot
8-K ·Filed Jun 18, 2026

DNLI

Denali Therapeutics Inc.
BULLISH
Impact 6/10
Horizonweeks Processed5mo ago SEC0001714899-26-000081
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

The $195M cash infusion is a significant non-dilutive capital event for a clinical-stage biotech with a $3.7B market cap. Monitor HSR clearance timeline for closing. The proceeds extend Denali's cash runway and de-risk pipeline advancement, watch for upcoming clinical data readouts on DNL126 (Sanfilippo), DNL593 (FTD), and DNL628 (Alzheimer's) as key catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$23.31
T+0 close · Jun 18, 2026 · via day close
Latest settled
−8.97%
T+60 · $21.22
Vs SPY
−10.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 18 $23.31entry
  2. T+1 · 5mo ago +3.17%α +3.49% · $24.05
  3. T+5 · 5mo ago +6.09%α +7.76% · $24.73
  4. T+20 · 4mo ago −2.49%α −3.02% · $22.73
  5. T+60 · 2mo ago −8.97%α −10.86% · $21.22
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Denali Therapeutics (DNLI) announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million in cash. The PRV was awarded following the March 2026 FDA approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome. The $195M cash infusion is a non-dilutive capital event that strengthens Denali's balance sheet and provides funding to advance its broad clinical pipeline of TransportVehicle-enabled programs for lysosomal storage disorders and neurodegenerative diseases, including Sanfilippo syndrome, frontotemporal dementia, Pompe, and Alzheimer's. The transaction is subject to customary HSR closing conditions.

Key Financial Metrics

Deal Value
$195.0M

Key Facts

  • Denali entered an asset purchase agreement to sell its Rare Pediatric Disease PRV for $195 million in cash on June 12, 2026
  • PRV was awarded following FDA accelerated approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome (MPS II) in March 2026
  • Proceeds will fund advancement of clinical pipeline including ETV, OTV, and ATV programs for multiple lysosomal storage disorders and neurodegenerative diseases
  • Transaction subject to customary closing conditions including HSR antitrust waiting period expiration
  • AVLAYAH is the first FDA-approved biologic designed to cross the blood-brain barrier via transferrin receptor-mediated transport

Financial Impact

$195 million non-dilutive cash infusion from PRV sale

cashcash runwaybalance sheet

Risk Factors

  • PRV sale subject to HSR clearance, closing could be delayed
  • Clinical-stage pipeline still unapproved; AVLAYAH is only approved product

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001714899-26-000081
Document: pressreleasedatedjune182026.htm0001714899-26-000081
Document: 0001714899-26-000081-index-headers.html0001714899-26-000081
Document: 0001714899-26-000081-index.html0001714899-26-000081
Document: 0001714899-26-000081.txt0001714899-26-000081

Track record

17 reports on DNLI

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +23.19% at T+60 after the May 7, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.75 Now $18.08 −3.55% settles Nov 17
  2. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  3. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $20.96 to $19.72 Now $18.08 −13.74% ▼ −5.92% −1.51% vs SPY
  4. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $18.94 to $18.86 Now $18.08 −4.54% ▼ −0.42% +0.06% vs SPY
  5. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $18.66 Now $18.08 −3.11% No price data
  6. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $21.40 to $21.09 Now $18.08 −15.51% ▼ −1.45% −2.30% vs SPY
  7. Sep 4, 202610w ago Insider Cluster Neutral 2/10 Entry $22.08 to $21.57 Now $18.08 −18.12% ▼ −2.31% −1.84% vs SPY
  8. Aug 6, 202614w ago 8-K Mixed 6/10 Entry $24.83 to $25.00 Now $18.08 −27.18% ▲ +0.68% +0.71% vs SPY
  9. Jul 27, 202616w ago Press Release Neutral 1/10 Entry $24.05 Now $18.08 −24.82% No price data
  10. Jun 18, 202621w ago 8-K Bullish 6/10 Viewing Entry $23.31 to $24.05 Now $18.08 −22.44% ▲ +3.17% +3.49% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (9h 55m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 18, 2026